2m 2m 2m 2m 2m 2m 2m
BRIDGEBIO PHARMA (BBIO)
NASDAQ
$68.72-$0.20 (-0.30%)
Price as of Jun 23, 2026 7:09 PM EDT- $13.5BMarket Cap
- 63.41%1-Year Change
- BiotechnologyIndustry
BRIDGEBIO PHARMA (BBIO)
$68.72-$0.20 (-0.30%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 362.4M +63.30% | 221.9M +2,285.27% | 9.3M -88.02% | 77.6M +11.38% | |
Cost of Revenue | 15.7M +304.51% | 3.9M +58.54% | 2.4M N/A | N/A N/A | |
Gross Profit | 346.7M +59.01% | 218.0M +3,079.58% | 6.9M -91.17% | 77.6M +15.93% | |
Sales and Marketing Expense | 531.2M +83.86% | 288.9M +91.87% | 150.6M +5.17% | 143.2M -25.50% | |
Research and Development Expense | -452.0M -10.76% | -506.5M +11.14% | -455.7M +14.08% | -399.5M -11.43% | |
Depreciation and Amortization Expense | 5.4M -10.55% | 6.1M -6.45% | 6.5M -4.09% | 6.8M +15.88% | |
Total Operating Expenses | 1.0B +25.85% | 814.9M +32.14% | 616.7M +4.55% | 589.9M -8.74% | |
Operating Profit | -523.4M -11.73% | -593.0M -2.37% | -607.4M +18.58% | -512.2M -11.17% | |
Interest Income | 19.9M +15.10% | 17.2M -4.37% | 18.0M +139.17% | 7.5M +565.67% | |
Interest Expense | -10.1M +21.30% | -8.3M -89.79% | -81.3M +1.06% | -80.4M +71.96% | |
Interest Income and Expense and Net | 9.8M +9.35% | 8.9M +114.15% | -63.3M -13.23% | -72.9M +59.70% | |
Total Nonoperating Income and Expense | -209.1M -511.77% | 50.8M +210.68% | -45.9M -266.54% | 27.6M +380.49% | |
Income before Taxes | -732.5M +35.10% | -542.2M -15.70% | -643.2M +33.67% | -481.2M -14.46% | |
Income Taxes | 435,000 -62.27% | 1.2M N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -732.9M +34.89% | -543.3M -16.82% | -653.3M +34.79% | -484.7M -17.36% | |
Net Income from Continuing Operations Applicable to Common | -724.9M +35.31% | -535.8M -16.70% | -643.2M +33.67% | -481.2M -14.46% | |
Basic EPS and Net Income | -3.78 +31.25% | -2.88 -27.09% | -3.95 +21.17% | -3.26 -16.41% | |
Diluted EPS and Net Income | -3.78 +31.25% | -2.88 -27.09% | -3.95 +21.17% | -3.26 -16.41% | |
Basic Weighted Average Shares | 191.5M +2.93% | 186.1M +14.30% | 162.8M +10.39% | 147.5M +2.16% | |
Diluted Weighted Average Shares | 191.5M +2.93% | 186.1M +14.30% | 162.8M +10.39% | 147.5M +2.16% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 570.1M -16.29% | 681.1M +81.18% | 375.9M -0.20% | 376.7M -4.34% | |
Short-Term Investments | 17.4M N/A | N/A N/A | 0 -100.00% | 51.6M -86.90% | |
Cash and Cash Equivalents and Short-Term Investments | 587.5M -13.75% | 681.1M +81.18% | 375.9M -12.22% | 428.3M -45.62% | |
Total Current Assets | 797.7M +10.69% | 720.7M +50.90% | 477.6M -12.98% | 548.9M -38.25% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 5.4M -23.46% | 7.0M -40.67% | 11.8M -18.90% | 14.6M -51.54% | |
Total Long-Term Assets | 16.7M -8.15% | 18.2M -19.58% | 22.6M +11.87% | 20.2M -38.77% | |
Total Assets | 936.0M +1.82% | 919.3M +68.26% | 546.4M -12.30% | 623.0M -38.48% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 288.0M +86.51% | 154.4M +7.34% | 143.8M +18.46% | 121.4M -10.10% | |
Total Long-Term Debt | 564.6M +29.09% | 437.3M -2.04% | 446.4M +3.59% | 431.0M +0.06% | |
Total Long-Term Liabilities | 244,000 -14.69% | 286,000 -96.94% | 9.4M -64.87% | 26.6M +20.73% | |
Total Liabilities | 3.0B +26.74% | 2.4B +25.84% | 1.9B +1.12% | 1.9B -0.55% | |
Retained Earnings | -3.8B +23.41% | -3.1B +20.92% | -2.6B +33.49% | -1.9B +33.49% | |
Total Stockholders Equity | -2.1B +42.15% | -1.5B +8.39% | -1.4B +7.94% | -1.3B +44.14% | |
Total Shares Outstanding | 194.8M +2.49% | 190.0M +8.55% | 175.1M +16.24% | 150.6M +2.23% | |
Cash Flow | |||||
Cash from Operating Activities | -445.9M -14.37% | -520.7M -1.33% | -527.7M +25.80% | -419.5M -15.75% | |
Capital Expenditures | 1.1M +17.58% | 933,000 -28.56% | 1.3M -72.91% | 4.8M -63.60% | |
Cash from Investing Activities | -24.5M -140.29% | 60.8M +12.49% | 54.0M -88.08% | 453.1M +325.64% | |
Dividends Paid | 2.1M N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 359.3M -52.00% | 748.5M +65.76% | 451.5M +3,537.91% | -13.1M -101.78% | |
Financials Ratio | |||||
Gross Margin | 95.67% -2.63% | 98.25% +33.30% | 73.71% N/A | N/A N/A | |
Operating Margin | -144.44% -45.95% | -267.22% -95.91% | -6,528.75% +889.74% | -659.65% -20.25% | |
Return on Assets | -79.01% +6.56% | -74.14% -33.64% | -111.72% +88.55% | -59.25% -13.29% | |
Return on Equity | 41.24% +7.10% | 38.51% -23.11% | 50.08% +9.79% | 45.61% -68.40% | |
Revenue Growth | 63.30% -97.23% | 2,285.27% +2,696.34% | -88.02% -873.62% | 11.38% -98.47% | |
Current Ratio | 2.77 -40.65% | 4.67 +40.58% | 3.32 -26.54% | 4.52 -31.32% | |
Cash Ratio | 1.98 -55.12% | 4.41 +68.79% | 2.61 -15.75% | 3.10 +6.41% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow